

Our Life Sciences and Healthcare sector focus

2023







Contents

Introducing Allen & Overy	04
Full service, international support for the life sciences and healthcare sector	05
M&A/corporate finance	06
Licensing and collaborations	09
Patent litigation	12
Regulatory	15
Dispute resolution/arbitration	16
Equity and debt financing	17
Restructuring	18
Key contacts	19

Introducing Allen & Overy

Global leader



One of only six firms to act on more than USD1.3 trillion worth of deals globally in 2021*


* Data sources: Refinitiv and Dealogic. Based on data from the live database on 1 February 2023 therefore figures could differ from published press releases.



40+

Over 40 offices around the world

Employees



Interest in legal technology and information remains high



130 16


applications across 25 countries to join Fuse, our tech innovation space

cohort companies – our biggest group ever

Disciplinary split by total number of lawyers (%)



Global presence



NORTH AMERICA

Boston
Los Angeles
New York
San Francisco
Silicon Valley
Washington, D.C.

CENTRAL & SOUTH AMERICA

São Paulo

EUROPE

Amsterdam
Antwerp
Belfast
Bratislava
Brussels
Budapest
Dublin
Düsseldorf
Frankfurt
Hamburg
Istanbul
London
Luxembourg
Madrid
Milan
Munich
Paris
Prague
Rome
Warsaw

AFRICA

Casablanca
Johannesburg

MIDDLE EAST

Abu Dhabi
Dubai

ASIA PACIFIC

Bangkok
Beijing
Hanoi
Ho Chi Minh City
Hong Kong
Jakarta*

Perth
Seoul
Shanghai
Singapore
Sydney
Tokyo

* Associated office

Full service, international support for the life sciences and healthcare sector

We have a multi-disciplinary team focusing on the Life Sciences and Healthcare sector. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, medtech, and diagnostics sectors.

Our team covers the full spectrum of legal support. We advise on mergers and acquisitions, commercial transactions (including licensing and collaborations), IP (both contentious and non-contentious), capital markets and finance, regulatory matters and dispute resolution.

Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are well positioned to advise on cross-border work.

“The standard of the work carried out by the A&O team is the absolute highest. They are working at the highest level for the busiest and most interesting of clients.”

Legal 500 2021 (Life Sciences and Healthcare)

M&A/corporate finance

The combination of our leading M&A practice and our specialisation in the life sciences and healthcare sector differentiates us from other international firms in the M&A market. We have a reputation for getting to the heart of the most complex issues, focusing on strategy, structuring issues and minimising execution risk. Our team advises on the full range of M&A transactions from smaller, mid-tier transactions to cross-border, complex acquisitions. We have experience advising on all forms of acquisitions, including full business and asset sales, asset swaps and the acquisition of stakes in companies.

Reckitt Benckiser

On the proposed sale of its E45 brand and related sub-brands to Karo Pharma for an implied enterprise value of GBP200 million.

Bridgepoint Advisers Limited

A UK private equity house, via its portfolio company PharmaZell on their acquisition of French Groupe Novasep from private equity houses Silver Point Capital and Blackrock. We also advised on a transaction-related financing.

Q2 Solutions

A leading global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA, Inc. in connection with the sale of Nexelis, a portfolio company of Ampersand Capital Partners.

A.P. Moller Holding

On the acquisition of Unilabs, the leading European provider of medical diagnostics services.

Kiadis Pharma

A Dutch clinical stage biopharmaceutical company, on the EUR308m public offer by Sanofi, an international pharmaceutical company.

Novartis

On its USD52 billion acquisition of a majority stake in Alcon, a global leader in eye care.

A global healthcare company

On its acquisition of the 80.1% of the shares in Cellzome, that it does not already own, from various institutional and individual sellers. The effective consideration is GBP61m.

Our expertise and local knowledge in the M&A market ensure that we deliver cost-effective, seamless, high-quality legal advice. Our strong teamwork and uniform approaches are vital to ensuring that cross-border deals are managed effectively. Efficient working practices and commercial pricing enable us to deliver 'more for less'.

Omega Pharma

On its EUR470m acquisition of the non-core OTC brands of GlaxoSmithKline in Germany, the UK, Poland and Italy.

Mediq

On its USD1bn public takeover by Advent International and subsequent delisting.

BTG

On its GBP3.3bn takeover offer by Boston Scientific, the U.S.-based medical technology company.

Crucell

On its EUR1.75bn public takeover by Johnson & Johnson.

Walgreens

On its acquisition of a USD6.7bn 45% stake in Alliance Boots, the leading international pharmacy-led health and beauty group, with an option to acquire the remaining 55% stake in three years.

Reckitt Benckiser

On its acquisition of Oriental Medicine Company Limited, a Hong Kong holding company for three operating companies in China (trading under the name "Golong Pharmaceutical"), which produce and distribute over-the-counter health products and traditional Chinese medicine products.

Abraaj Capital (Cayman) Limited

On its acquisition of 50% of Turkish hospital operator Acibadem Health Services for approximately USD470m. Acibadem Health Services is Turkey's largest health services company and is listed on the Istanbul Stock Exchange.

“It was stellar team performance and we benefited from the pure value contributed.”

Client quoted in Chambers Global 2021
(Life Sciences: Europe-wide)

Biomet

On the USD300m acquisition of Merck KGaA's 50% stake in the Dutch orthopaedics and biomaterials joint venture BioMer C.V. between Biomet, Inc and Merck KGaA.

Grünenthal

On its acquisition of AstraZeneca's European rights to prescription Nexium and the global (excluding the U.S. and Japan) rights to Vimovo for USD922m.

GE Healthcare

On its agreement to acquire PAA Laboratories, a worldwide distributor of cell culture products; on the sale of its patient statement printing and mailing services business; on its acquisition of VersaMed; on its USD100m acquisition of the assets of Dynamic Imaging; and on its acquisition of Wave Biotech's bioreactor business.

Nikko Principal Investments

On the disposal of its 80% partnership interest in UK Healthcare Limited Partnership.

A global biopharmaceutical company

On the acquisition of Paradigm Therapeutics, including an assessment of its IP portfolio.

UCB

On the disposal of certain over-the-counter products to Pierre Fabre and the disposal of its non-core product portfolio to various purchasers.

Société Régionale d'Investissement de Wallonie

On the USD305m sale of its stake in Uteron Pharma, a Belgian female healthcare company, to Watson Pharmaceuticals, a listed U.S. pharmaceutical company.

Adamed Pharma

On the acquisition of shares in Pabianickie Zakłady Farmaceutyczne Polfa, one of the largest state-owned producers of pharmaceuticals in Poland. This was one of the most significant over-the-counter privatisation transactions.

“There were no inefficiencies, it was seamless.”

Client quoted in Chambers Global 2021
(Life Sciences: Europe-wide)

Circassia Pharmaceuticals plc

On its acquisition of Aerocrine AB and Prosonix Limited, both funded through a GBP275m placing and open offer.

Merck KGaA

On a number of corporate matters, including the acquisition of Biochrom; the acquisition of Biotest and the acquisition of the IP portfolio of the insolvent Konarka group by way of an auction process within a U.S. insolvency procedure pursuant to Chapter 7 of the U.S. Bankruptcy Code.

The owners of Omega Pharma

On the EUR3.6bn sale of Omega Pharma, the Belgium-based manufacturer and distributor of healthcare products (including over-the-counter drugs), to Perrigo, a U.S.-listed, Ireland-incorporated pharmaceutical company.

DSM

On its merger with Firmenich, becoming the global leading creation and innovation partner in nutrition, beauty and well-being.

GN Store Nord A/S

On its investment and merger of its subsidiary with Lively, an online hearing care and digital marketing platform.

Frame Cancer Therapeutics

A private company focused on developing personalised cancer immunotherapies, on the EUR32m sale of 100% of its shares to CureVac, a global biopharmaceutical company.

Symbio

A joint venture between Michelin and Faurecia, on the establishment of a 50:50 joint venture with Schaeffler Group to produce fuel cell bipolar plates.

Xinvento

On its Series Seed funding round, in which Xinvento was financially backed by drug development experts and seasoned biotech leaders. Xinvento Series Seed will enable it to design and test its proprietary molecules in the relevant pre-clinical models to identify potential drug candidates.

Babylon Health

On the USD4.2bn SPAC merger with Alkuri Global, a Nashville based blank check firm

Bayer AG

On the sale of its men's health product Nebido™ (testosterone undecanoate) to Grünenthal for a purchase price totalling up to EUR500 million.

Progress Medical

On its acquisition of 90% of the shares in OB Klinika, a surgical clinic in Prague, offering medical services in aesthetic, bariatric, orthopaedic, and dental and jaw surgery.

Syntaxin

A leader in recombinant botulinum toxin technology, on its acquisition by Ipsen for an upfront payment of EUR28m and milestones with a potential value in excess of EUR130m.

Novartis

On the disposal of its 43% stake in LTS Lohmann Therapie-Systeme AG to dievini Hopp BioTech holding GmbH & Co. KG. The disposal has been agreed in co-operation with co-investor BWK GmbH Unternehmensbeteiligungsgesellschaft which is also selling out to dievini.

Novartis

On the USD1.7bn sale of its Emeryville California-based Diagnostics Unit to Grifols.

SmartPractice

The global leader in diagnostic patch test allergens and chambers for the diagnosis of allergic contact dermatitis, on the acquisition of Epicutantest Hermal/TROLAB patch test business from Almirall.

Dubai Investments

On the sale of 66% stake in Globalpharma to Sanofi and a third party. We advised on the share sale agreement and a suite of operational agreements to be entered into between Globalpharma Company LLC and Sanofi group companies.

EC de Witt

The UK subsidiary of U.S. firm CB Fleet, on the sale by competitive auction of its European speciality pharmaceuticals business to Recordati España.

JHI

The international arm of Johns Hopkins Medicine, on the acquisition of a stake and a joint venture with Saudi Aramco to establish a new healthcare provider for Saudi Aramco. This is a significant deal as it represents the first time an American institution has invested in healthcare in Saudi Arabia.

Soho Global Health

A leading Indonesian pharmaceutical business, on the sale of a strategic stake in its ethical pharmaceutical business to Fresenius and the related joint venture arrangements.

Optos

On the proposed offer by Nikon Corporation for the entire issued and to be issued share capital of Optos.

Deb Group

A portfolio company of existing client Charterhouse Capital Partners, on Deb Group's acquisition of the Stoko Professional Skin Care business from Evonik Industries.

Kladis Pharma

A Dutch clinical stage biopharmaceutical company, on the EUR308m public offer by Sanofi, an international pharmaceutical company.

Apax Partners and its portfolio company Neuraxpharm Group

On the acquisition of the assets and rights related to prescription brand Buccolam® in 15 countries from Takeda Pharmaceutical Company Ltd.

“Well regarded for its impressive client portfolio, which spans the pharmaceutical, biotechnology, medtech, diagnostics and healthcare industries.”

Chambers Global 2018 (Life Sciences: Global-wide)

Licensing and collaborations

We have a proven track record of advising clients on strategic licensing, joint venture and collaboration arrangements, manufacturing and distribution agreements and co-marketing and co-promotion agreements in the life sciences and healthcare sector.

As well as the structuring, drafting and negotiation of licensing and collaboration deals, we can assist clients with the analysis of in-licensed IP and the potential for licensors to exploit those rights, as well as on the strategy for, and consequences of, terminating or exiting licensing/collaboration arrangements, including in circumstances where one party becomes bankrupt or insolvent. Furthermore, we advise clients on raising funds using royalty streams from licence agreements.

We also advise on outsourcing contracts (including issues such as contract research, and procuring third-party support

on clinical trials), services agreements, software licensing and development agreements, product agreements and white labelling agreements.

Clients value the calibre of our team, the quality of our legal expertise and our ability to negotiate robust agreements. Key to our success is the ability to combine the technical skills of our professionals with the business needs of our clients. We proactively help our clients to understand and deal with issues that arise in a commercial manner that fits in with their business objectives.

Our lawyers are able to draw upon the knowledge and experience of colleagues in our Tax, Antitrust, IP and Finance teams to offer a fully integrated service on the most complex licensing structures.

Abdul Latif Jameel Health

On the strategic collaboration with Evelo Biosciences to develop and commercialise novel therapy EDP1815 for inflammatory diseases and Covid-19.

Pfizer

On an innovative agreement with GlaxoSmithKline to create a HIV joint venture, ViiV, and subsequently on the amendment to this arrangement to bring on board the Japanese pharmaceutical group Shionogi.

Amarna Therapeutics

On several strategic collaboration agreements with investors and research institutions.

Cambridge Laboratories

On a number of pharma product, research, collaboration and licence agreements; and on the licensing of marketing and distribution rights for its drug Tetrabenazine.

A global healthcare company

On its licence and manufacturing agreement with MolMed for viral vectors and gene therapy products.

Merck Millipore

On the negotiation and drafting of a development agreement.

Novartis Pharma

On a software licensing agreement with Microsoft for the development of an IT healthcare platform to monitor patients remotely.

GE Healthcare

On a number of licensing and collaboration agreements and separation issues in connection with the disposal of a group.

UCB

On strategic global collaborations with Biogen, ImClone, Immunomedics, Amgen and Millennium regarding the research, development and commercialisation of various products, including advising on the application of the Hart-Scott-Rodino Act.

Pfizer

On a range of technical collaboration and funding arrangements with PRC universities and research institutes.

Biomet 3i

On its termination of its collaboration with Renishaw in relation to the distribution of dental scanners.

Syntaxin

On strategic development and licensing agreements with Ipsen relating to the use of botox in a therapeutic environment.

Shionogi

On its strategic collaboration with F2G Ltd to develop and commercialize a new antifungal agent, 'Olorofim' for invasive fungal infections in Europe and Asia.

A UK biotech start-up

On its agreements with various customers, for the use of its proprietary robotic drug discovery platform.

A major pharmaceutical company

In the preparation of a framework collaboration agreement for the development of digital health solutions.

Janssen Pharmaceutica

On an outsourcing project of analytical development services with a global leader in the testing, inspection and certification of products.

Mubadala/Cleveland Clinic

On a master services agreement with IBM in relation to the IT infrastructure of the Abu Dhabi Cleveland Clinic facility.

Thrombogenics

On a series of template IP collaboration agreements, including a master services agreement and a clinical testing services agreement.

A biobank institution

On various commercial and IP issues, including the negotiation of an agreement with a third-party provider of gene analysis services and the drafting of a collaborative research agreement.

GN Resound

On an agreement with Cochlear, pursuant to which GNR licensed its wireless technology to Cochlear for use in connection with cochlear implants, and also agreed to undertake certain development work.

Novartis Consumer Health Services

On its existing distribution arrangements in the context of recently introduced regulations by the Qatari Health Authorities.

A global healthcare company

On the establishment of a joint venture with Dai Ichi Sankyo to develop and distribute vaccines in Japan.

Vernalis

On its exclusive collaboration option and licence agreement with GlaxoSmithKline relating to a Vernalis research programme against an undisclosed oncology target; on the licensing of the Canadian rights to its Frova product; on an IP-backed financing under which Vernalis raised funding using the royalty streams from its licensing arrangements for frovatriptan; and on its EUR18.4m royalty financing agreement with Paul Capital Healthcare.

Consort Medical

On a collaboration with an international pharmaceutical company for the development, and if development is successful, the manufacture and supply, of a new medical device to be used for drug delivery. The agreement covers extensive R&D, the building of a new plant and long-term supply commitments.

Almac

On reviewing and amending a licence agreement with Aerial Pharma relating to the supply of products.

Multiplicom

A spin-off from the University of Antwerp which develops, manufactures and commercialises genetic test kits based on the latest molecular diagnostic technologies, on a number of contracts with suppliers and customers.

St. Jude Medical

On entering into a partnership with a major university in the Netherlands with regard to the development of new medical equipment for treating heart failures. St. Jude Medical received a grant from the Dutch Government for this research. We advised them on the entitlement to patents that were applied for, and that could be granted with regard to the results of the research. We carried out a general review of the terms of the partnership, the scope of protection of the relevant patents in relation to the research, and advised St. Jude Medical on the best strategy for approaching this matter.

Celyad

Formerly known as Cardio3 Biosciences, we advised on the acquisition of OnCyte, the oncology division of Celdara Medical, a U.S. biotechnology company, as well as its portfolio of immuno-oncology product candidates. Separately we also advised on the creation of a joint venture with Medisun International, a financial investor based in Hong Kong.

Allergopharma

On the establishment of a joint venture with Global Asthma and Allergy European Network (GA²LEN), Laboratorios Leti (Spain) and Stallergènes (France) for the development, the utilisation and the commercialisation of mobile exposition chambers.

A multinational pharmaceutical corporation

On the negotiation of a global technology license and services agreement with EMC Computer Science for the storage of submission related data.

Virgin Plants

On a Research and Development Agreement with the Leibniz Institute of Plant Genetics and Crop Plant Research.

Exscientia

On a series of collaborations with pharmaceutical partners for the deployment of Exscientia's AI drug discovery technology in relation to various drug discovery targets, including its USD5.2bn strategic research collaboration with Sanofi to develop an AI-driven pipeline of precision-engineered medicines and its research and development collaboration agreement with GT Apeiron Therapeutics.

A global healthcare company

On the EUR150m investment into, and strategic collaboration with, German biotech company CureVac for research development and commercialisation of mRNA-based vaccines and monoclonal antibodies targeting infectious diseases.



Patent litigation

We act for the world's leading companies in major multi-jurisdictional and national patent disputes across all sections of the life sciences and healthcare industry. We represent our clients in the many different courts and tribunals worldwide which are important in patent matters.

Our Patent teams are adept at exploiting the different procedural and tactical possibilities these forums offer. This includes, for example, securing evidence, obtaining fast interim relief or obtaining a favourable hearing. This enables us to co-ordinate litigation and settlement strategies to achieve the right outcome for our clients.

Frequently, a firm technical understanding is crucial to securing success: many of our lawyers have technical backgrounds and industry experience and can advise clients with confidence in cases involving the most complex technology. This includes team members with degrees in natural sciences, structural molecular biology and biochemistry.

We also advise our clients on the interplay between patent litigation strategy and regulatory matters. This axis has assumed increasing importance in the courts in recent years, particularly when dealing with Supplementary Protection Certificates, Paediatric Extensions and matters relating to data exclusivity.

Chinese companies of the Beijing Genomics Institute (BGI) group

The main challenger in the field of genetic sequencing, regarding a dispute against the market leader, Illumina Cambridge. The patents at stake involve extremely complex DNA sequencing technology, including machines, reagents and nucleotides.

A global pharmaceutical and healthcare company

On advising and representing the company in enforcing and defending validity of their SPC covering Losartan against generics of Losartan + HCTZ. This case was a premiere in Europe raising the issue of interpretation of Articles 4 and 5 of the SPC Regulation on the scope of protection of SPCs and paediatric extensions.

Pfizer

In enforcing its second medical use patent for its blockbuster, Lyrica (pregabalin), against Actavis and a large number of generic companies in the UK, France and Germany.

Abbott

In a number of patent disputes relating to vascular stents in France, part of an international battle against Evysio and Medtronic with related cases in the U.S., the UK, Germany, Ireland and the Netherlands, including obtaining a declaratory judgment of noninfringement in France (a route rarely used there).

Novartis

On a multi-jurisdictional biotechnological patent dispute (against MedImmune, part of Astra Zeneca) relating to the blockbuster drug Lucentis. This involved detailed understanding of molecular biology, antibody engineering and phage display screening technology.

Abbott

On obtaining the first preliminary injunction in a patent infringement case in the history of the Beijing courts.

Novartis

On a case where we obtained, in less than 3 days, a preliminary injunction against Sanofi's generic, which was launched three weeks before the expiry of Novartis' supplementary protection certificate. This case was a premiere in France where an injunction was ordered on an ex-parte basis, prohibiting the marketing of Sanofi's generic products in 24 hours. The ex-parte order was confirmed inter partes upon appeal of Sanofi in 48 hours.

Ambu

On its pan-European strategy and advice in relation to parallel national patent infringement and nullity actions in connection with its market-leading medical device (laryngeal masks).

“They have outstanding communication.”

Chambers Global 2021 (Life Sciences: Europe-wide)

A global pharmaceutical company

On its market leading reference to the CJEU on an SPC for a combination product.

A global healthcare company

On global surveys and conclusions on patent erosion in emerging markets and on criminal offences for patent infringement.

A global pharmaceutical and healthcare company

In an infringement action against Teva who launched its generic before the expiry of the company's supplementary protection certificate.

A multinational pharmaceutical corporation

On obtaining a preliminary injunction against off-label use that infringes Novartis' patent by a generic company in Beijing. This was the first preliminary injunction of this kind in China.

A multinational pharmaceutical corporation

As exclusive licensee of Genentech's patent, we advised in relation to patent revocation and DNI proceedings brought by Regeneron/Bayer to clear a path for “Eyelea” in the UK, France, Germany and Italy. We worked with Genentech's legal counsel on case strategy, with a successful outcome for Genentech and Novartis both at first instance and on appeal.

Pfizer

In an action brought by Actavis in the UK to revoke Pfizer's patent protecting its extended-release formulation of pramipexole – a treatment for Parkinson's disease. We successfully obtained the key strategic objective of the case by obtaining a stay of the English proceedings pending the EPO Opposition. This has maintained the status quo across Europe pending the outcome of the EPO Opposition.

Regeneron Pharmaceuticals

On its global patent enforcement strategy. This includes initiating patent infringement proceedings in the UK (against Kymab and Novo Nordisk) and in the Netherlands (against Merus) as well as assisting in the coordination of the global case (which includes litigation in New York and patent opposition proceedings at the European Patent Office (EPO) in Munich).

Angiotech Pharmaceuticals

On enforcement issues relating to its patent portfolio in Europe.

Beckman

In a patent infringement dispute with Oxford Gene Technology over nucleotide chip devices, including an appeal to the English Court of Appeal.

Biomet

On numerous cases in relation to patents covering prosthesis.

Degussa

In a dispute with Novus regarding the bio-efficacy of natural methionine versus synthetic methionine.

Electro Medical Systems and Ferton

In several patent litigation cases in relation to technology covering dental cleaning devices and medical instruments for treating biological tissue.

Guerbet

In a dispute concerning patents covering medical devices.

Haselmeier

In nullity and appellate proceedings initiated by Novo Nordisk.

Inverness Medical

On the cross-border enforcement of its patented rapid immunoassay technology.

KCI

In a patent licence dispute against Dr. William Fleischmann regarding patents in the area of medical devices for use in the field of wound care, tissue repair and tissue engineering.

A global pharmaceutical and healthcare company

Advice and representation on nullity actions against the company's patent covering dosage regimen. This case was raised for the first time before the French Courts on the issue of patentability of dosage regime claims.

Novozymes

In a patent infringement dispute against Danisco in relation to enzymes for the production of second generation biofuels.

Purac Biochem

On patent infringement proceedings in the field of biodegradable polymers used for pharmaceutical purposes.

Pfizer

On the validity of its paediatric extension to its Supplementary Protection Certificate (SPC) for the world's largest pharmaceutical, Lipitor, in the UK and across Europe, in response to a challenge from Dr Reddy's.

A global pharmaceutical and healthcare company

On an English High Court patent action against Genentech to achieve freedom to operate and commercial certainty in relation to the healthcare company's anti-IL-17 antibody, Taltz, in five countries.

A multinational genomics company

On a dispute with a major patent portfolio owner relating to integrated systems for the analysis of genetic variation and function. The dispute arises from the patentee's attempts to seek licence fees in relation to a patent pool that it is party to with another major player in genetic sequencing. We have been advising our client on strategy for defending these claims on a pan-European basis, as well as in Asia.

A global pharmaceutical and healthcare company

In preparing for a possible injunction in relation to an alleged infringement of patent and trade secret rights. A competitor claims that one of our client's products is infringing a patent portfolio recently acquired by the competitor. We have been developing the defense strategy, which includes drafting protective letters and a cease and desist manual.



Regulatory

We have diverse experience of providing regulatory compliance counselling to clients in the life sciences and healthcare industry and we advise on regulatory matters in a wide range of contexts, including patent litigation and due diligence as part of M&A or other commercial transactions. We advise on issues including clinical trials, product approval, marketing and advertising, internet and social media issues, data protection, product recalls, price and reimbursement issues, data-exclusivity, fraud and anti-corruption.

Novartis

In proceedings before the Conseil d'Etat (the highest administrative Court in France) with regard to the regulatory registration process of one of its pipeline products.

The French Pharmaceutical Trade Association (LEEM)

On various regulatory and IP issues.

Thrombogenics

On legal issues relating to clinical trials.

UCB Pharma

On a potential contractual dispute and the possibility of invoking the “not” exception for (pre)clinical trials.

A global healthcare company

On regulatory, warehousing and distribution issues relating to their operations in Slovakia.

A global pharmaceutical and healthcare company

On various employment law issues and regulatory, advertising and compliance issues relating to new pharmaceutical legislation in Slovakia.

Synthes

On the compliance and enforceability under Belgian law of its corporate policies on relationships with doctors; also on regulatory, advertising and compliance issues relating to medical devices.

Pfizer

On the reimbursement and distribution of vaccines.

Leo Pharma

A developer and manufacturer of dermatologic and thrombotic drugs, on the regulatory aspects of web-based patient support programmes under Belgian law.

GE Healthcare

On the issue whether “medical devices” can be exempted from complying with the revised EU “restriction in hazardous substances” (“RoHS2”) Directive, as they qualify as Large Scale Fixed Installations (“LSFI”).

Millennium Pharmaceutical

On regulatory aspects for the supply agreement of certain pharmaceutical products in Italy.

Novartis

On a global technology agreement with Cegedim Relationship Management, for the processing of data Novartis is required to collect and submit regarding certain payments and items of value given to physicians and teaching hospitals under the Physician Payments Sunshine Act.

Crucell Holland

A subsidiary of Janssen Pharmaceutica, on the contracts for the European Commission’s IMI 2 grant that it has received for developing an Ebola vaccine.

Reckitt Benckiser

In relation to proceedings commenced by the ACCC in the Federal Court of Australia.

Dispute resolution/arbitration

We have extensive experience of advising on commercial and contract disputes. In addition, we are seen as experts in advising board members and senior-level executives in relation to corporate risk management. We actively pursue alternative avenues of dispute resolution and advise on choosing the method most appropriate to our clients and the requirements of a particular matter. We have significant experience of mediation, arbitration and negotiation across our global network.

A leading international pharmaceutical company

In an internal investigation concerning alleged conflicts of interest and potential bribery by its procurement department in a private tender process.

An Australian medical research company

On a sophisticated business email compromise fraud, of which it was the victim. We commenced immediate civil recovery action and successfully obtained proprietary and Mareva injunctions against the fraudsters in the High Court of Hong Kong, as well as advised the client on litigation strategy and the relevant disclosure to the public regarding the fraud. The client obtained full recovery of all monies known to remain within Hong Kong.

A pharmaceutical company

On a criminal complaint by a former manager who was dismissed as a consequence of a whistle-blowing procedure.

A healthcare information, services and technology company

An American multinational company serving the combined industries of health information technology and clinical research, in relation to a post M&A dispute before the Paris commercial court.

Biomet

In several dozen product liability cases in France and the Netherlands including a product liability claim from a patient for a broken reamer and a potential counterclaim against the hospital regarding techniques used during the operation.

Hoya Surgical Optics

In a contractual and trademark litigation against a former distributor concerning medical devices for implanting intraocular lenses.

Novartis Pharmaceuticals Hong Kong/Honbase Trading

On an ICC arbitration in Hong Kong under Dutch law regarding the alleged unlawful termination of a distribution relationship.

Novartis Vaccines and Diagnostics

In a product liability case concerning the purchase of defective syringes and on litigation matters related to public procurement issues.

St. Jude Medical Japan

In proceedings against the trustees and certain hedge fund investors in the bankruptcy of Jomed in three instances regarding a claim under a Convertible Loan Agreement, which the trustees and the hedge funds argued to be void.

U.S. contract manufacturer

On an ICC arbitration over misappropriation of patented technology and know-how and breach of confidentiality undertakings.

St. Jude Medical

In several product liability matters including against multiple claims following a product recall of the Riata lead (a lead which connects an implantable cardioverter defibrillator (ICD) to the heart in order to monitor heart rhythms).

A manufacturer of medical devices

On litigation relating to the termination of a distribution agreement/refusal to sell.

A life sciences client

On potential investment treaty claim against Hungary as a result of various changes to pharmaceutical regulations and taxation.

Equity and debt financing

We advise on some of the most complex and high-profile equity and debt offerings. Our experience with companies operating, listing or offering securities in multiple jurisdictions means that our clients benefit from integrated U.S. and English law capability. Our lawyers can advise on the full spectrum of equity and equity-linked instruments, including secondary offerings, rights issues, quick-to-market transactions and block trades, as well as convertible and exchangeable bond issues.

Our Debt Financing practice is widely recognised as the market leader across a variety of sectors including life sciences and healthcare. Our knowledge of advising domestic and international borrowers and financiers means that we can advise on all types of financing transactions. We have unrivalled experience advising a wide range of participants in the loans market involved in bank financings and international capital markets transactions. Our Debt Financing practice continues to be ranked top tier in all the latest editions of the leading legal directories, including Chambers UK, Legal 500 and IFLR1000.

Guosen Securities and CCB International

As joint sponsors to the global offering and listing of Immunotech Biopharm on the Hong Kong Stock Exchange.

ThromboGenics

On its EUR78m private placement with accelerated book building with domestic and international investors and qualified institutional buyers in the U.S. and the listing of the new shares on NYSE Euronext Brussels.

Fresenius Medical Care

On multiple financings, including the fully syndicated EUR3.1bn financing for its unsuccessful June 2012 bid to acquire German hospital operator Rhoen-Klinikum.

Vernalis

On its GBP30.3m placing and open offer on the London Stock Exchange (LSE) and subsequent GBP42.7m capital increase.

UCS

On the financing of Actavis' bid for Pilva, the generic drug producer.

The arrangers

On the debt financing supporting KKR, Bain Capital and Merrill Lynch Global Private Equity's USD33bn acquisition of HCA (a hospital operator in the U.S.).

A British multinational banking and financial services company

As mandated lead arranger on the USD650m acquisition financing of U.S.-based Decision Resources Group by Piramal Healthcare of India.

Celyad

Formerly Cardio3 BioSciences, a leader in the discovery and development of cell therapies, we advised in its EUR23m IPO on Euronext Brussels and Paris and on the EU aspects of its USD100.1m IPO on NASDAQ and on its EUR32m pre-round private placement with investors in the United States and Europe.

The mandated lead arrangers

On a refinancing for the Euromedic group, under which the existing senior and mezzanine facilities made available to the group were refinanced on the disposal of the group's dialysis business.

Circassia Pharmaceuticals

On its GBP580m IPO and admission to both the premium listing segment of the Official List and to trading on the LSE.

A global financial institution

On the capital increase of MorphoSys raising gross proceeds of approximately EUR84m in a private placement via an accelerated book building procedure.

NMC Health

On its IPO on the LSE. This was the first premium listing of an Abu Dhabi company on the LSE.

Société Générale

On the credit revolving facility for Ipsen.

Restructuring

Our presence in the restructuring market is truly international. Fielding one of the largest international teams, we are known as one of the few practices with the ability to advise on extremely complex cross-border transactions. We aim to bring pioneering ideas to our clients' transactions, advising on every single part of the capital structure. This is important as restructurings become more and more multi-faceted, demanding wide market experience, deep knowledge of the sector and specialist legal knowledge. Restructurings within the life sciences and healthcare sector require a specific sense of the challenges related to this regulated context.

Covidien

On its multi-billion dollar multi-jurisdictional group reorganisation and spin-off to its shareholders of its pharmaceuticals business under a new holding company named Mallinckrodt.

USP Hospitales

Advised the facility agent and the lenders on restructuring of USP Hospitales.

KCI Europe

On the design and co-ordination of its restructuring.

OCMW/ZNA (Hospital Network Antwerp)

The sixth biggest hospital entity in Europe, on all legal aspects of a major restructuring and partial privatisation, and subsequently on: the legal aspects of all hospital-strategic matters, including employment, policies with regard to doctors, industrial relations, procurement, cooperations, government relations, tax optimisation, etc.

Four Seasons Health Care Group

Advised Servicer and Special Servicer of the Four Seasons Whole Loan (the senior facilities) and related security, in connection with the GBP1.75bn restructuring of the Four Seasons Health Care Group. The first restructuring concluded after 18 months of negotiation and documentation and involved implementation in six other jurisdictions involving 11 tranches of debt. The first restructuring was the first European CMBS whole loan serviced deal to be restructured and one of the biggest restructurings completed in the UK in 2009.

Restructuring advice comprises not only debt restructuring but also corporate restructuring including employment. Our global Employment group is a market-leading practice with expertise of local and global issues for both advisory and corporate transactional work. We possess extensive experience in wide programmes of change management, including reorganisations and collective lay-offs, as well as specific expertise in HR constraints and ramifications in merger and acquisition situations.

Kinetic Concepts (KCI)

On its international reorganisation covering multiple jurisdictions.

MBIA Assurance

In connection with the successful restructuring of the Craegmoor group. Craegmoor is a market leader in the provision of specialist care for adults, children and older people.

The steering committee banks of Merckle Group

In connection with the restructuring of Merckle Group and the sale of Merckle-Ratiopharm to Teva Pharmaceuticals, including the subsequent distribution of proceeds, and the comprehensive restructuring of the Phoenix pharmaceutical wholesale business.

Navis

On the purchasing of a 65% interest in OPV Pharmaceuticals, a Vietnamese generic drug manufacturer. This involved a pre-completion restructuring by the seller and the back-to-back exit of previous investors in the target and joint venture arrangements at the holding company level.

“The entire team has been extraordinarily responsive to every request. There is a high degree of business acumen combined with legal expertise that is difficult to be found otherwise in that specific combination...”

The Legal 500 2021 (Life Sciences and Healthcare)

Key contacts

Belgium



Laëtitia Bénard

Partner – IP

Tel +33 1 40 06 50 33

laetitia.benard@allenoverly.com



Jim Ford

Partner – IP/Commercial

Tel +44 20 3088 4797

jim.ford@allenoverly.com



Dirk Arts

Partner – Competition

Tel +32 2 780 2924

dirk.arts@allenoverly.com



Geert Glas

Senior Counsel – IP

Tel +32 2 780 2560

geert.glas@allenoverly.com

Belgium



Peter Van Dyck

Partner – Litigation, IP

Tel +32 2 780 25 12

peter.vandyck@allenoverly.com



Charles Pommies

Counsel – Competition

Tel +32 2 780 2936

charles.pommies@allenoverly.com



Jean-Claude Rivalland

Partner – Corporate

Tel +33 1 40 06 53 02

jean-claude.rivalland@allenoverly.com



Charles Tuffreau

Partner – Litigation, IP

Tel +33 1 40 06 51 43

charles.tuffreau@allenoverly.com

France



Hartmut Krause

Partner – Corporate

Tel +49 89 71043 5782

hartmut.krause@allenoverly.com



Stephan Neuhaus

Partner – Litigation, IP

Tel +49 211 2806 7130

stephan.neuhaus@allenoverly.com



Alexander Veith

Partner – Corporate

Tel +49 89 71043 3120

alexander.veith@allenoverly.com



Eda Zhuleku

Counsel – Corporate

Tel +49 89 71043 3125

eda.zhuleku@allenoverly.com

Germany

Netherlands



Christiaan De Brauw
Partner – Corporate
Tel +31 20 674 1298
christiaan.debrauw@allenoverly.com



Frits Gerritzen
Partner – Litigation, IP
Tel +31 20 674 1709
frits.gerritzen@allenoverly.com



Sophie Roozendaal
Partner – Corporate
Tel +31 20 674 1657
sophie.roozendaal@allenoverly.com



**Krystyna
Szczepanowska-Kozłowska**
Partner – Corporate
Tel +48 22 820 6176
krystyna.szczepanowska@allenoverly.com

Poland



Rafi Allos
Partner – Litigation, IP
Tel +44 20 3088 2164
rafi.allos@allenoverly.com



Matthew Appleton
Partner – Corporate
Tel +44 20 3088 3340
matthew.appleton@allenoverly.com



Marjan Noor
Partner – Litigation, IP
Tel +44 20 3088 2554
marjan.noor@allenoverly.com



Mark Ridgway
Partner – Litigation, IP
Tel +44 20 3088 3720
mark.ridgway@allenoverly.com

UK

UK



Kristina Nordlander
Partner – Competition
Tel +44 20 3088 1280
kristina.nordlander@allenoverly.com



Tom Butcher
Partner – Corporate
Tel +971 4 418 0414
tom.butcher@allenoverly.com

Middle East



Peter McDonald
Partner – Competition
Tel +61 2 9373 7582
peter.mcdonald@allenoverly.com

Australia



Eugene Chen
Registered Foreign Lawyer
(California) – Hong Kong
Tel +852 2974 7248
eugene.chen@allenoverly.com

Hong Kong

Hong Kong



Victor Ho
Registered Foreign Lawyer
(California) – Hong Kong
Tel +852 2974 7288
victor.ho@allenoverly.com



François Renard
Partner – Competition
Tel +852 2974 7110
francois.renard@allenoverly.com

China



Jill Ge
Partner – Litigation, IP
Tel +86 21 2036 7124
jill.ge@allenoverly.com



Jack Wang
Partner – Corporate
Tel +86 21 2036 7009
jack.wang@allenoverly.com

Japan



Tokutaka Ito
Partner – Corporate
Tel +813 6438 5046
tokutaka.ito@allenoverly.com



John Bennett
Partner – Litigation, IP
Tel +1 857 353 4504
john.bennett@allenoverly.com



Elizabeth Holland
Partner – Litigation, IP
Tel +1 212 610 6365
elizabeth.holland@allenoverly.com



Bill James
Partner – Litigation, IP
Tel +1 202 683 3895
william.james@allenoverly.com

U.S.



Daniel Margolis
Partner – Litigation, IP
Tel +1 212 610 6375
daniel.margolis@allenoverly.com



Nick Mitrokostas
Partner – Litigation, IP
Tel +1 857 353 4503
nicholas.mitrokostas@allenoverly.com



Sapna Palla
Partner – Litigation, IP
Tel +1 212 610 6389
sapna.palla@allenoverly.com



Elaine Johnston
Partner – Competition
Tel +1 212 610 6388
elaine.johnston@allenoverly.com

Global presence

Allen & Overy is an international legal practice with approximately 5,800 people, including some 590 partners, working in more than 40 offices worldwide. A current list of Allen & Overy offices is available at www.allenoverly.com/global_coverage.

Allen & Overy means Allen & Overy LLP and/or its affiliated undertakings. Allen & Overy LLP is a limited liability partnership registered in England and Wales with registered number OC306763. Allen & Overy (Holdings) Limited is a limited company registered in England and Wales with registered number 07462870. Allen & Overy LLP and Allen & Overy (Holdings) Limited are authorised and regulated by the Solicitors Regulation Authority of England and Wales.

The term partner is used to refer to a member of Allen & Overy LLP or a director of Allen & Overy (Holdings) Limited or, in either case, an employee or consultant with equivalent standing and qualifications or an individual with equivalent status in one of Allen & Overy LLP's affiliated undertakings. A list of the members of Allen & Overy LLP and of the non-members who are designated as partners, and a list of the directors of Allen & Overy (Holdings) Limited, is open to inspection at our registered office at One Bishops Square, London E1 6AD.